Article Versions Notes

To S-Y, Kao L-T, Shih J-H, Li I-H, Huang T-W, Tsai C-L, Chian C-F, Ho C-L, Chang P-Y. Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. International Journal of Environmental Research and Public Health. 2022; 19(10):5999. https://doi.org/10.3390/ijerph19105999

To, Sheng-Yin, Li-Ting Kao, Jui-Hu Shih, I-Hsun Li, Tsai-Wang Huang, Chen-Liang Tsai, Chih-Feng Chian, Ching-Liang Ho, and Ping-Ying Chang. 2022. "Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study" International Journal of Environmental Research and Public Health 19, no. 10: 5999. https://doi.org/10.3390/ijerph19105999

To, S.-Y., Kao, L.-T., Shih, J.-H., Li, I.-H., Huang, T.-W., Tsai, C.-L., Chian, C.-F., Ho, C.-L., & Chang, P.-Y. (2022). Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. International Journal of Environmental Research and Public Health, 19(10), 5999. https://doi.org/10.3390/ijerph19105999